Pueraria Mirifica
5 benefits mapped to clinical evidence across supplements.
Dose per serving from research
11 study groups in 5 studies say how much Pueraria Mirifica participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 25 mg to 50 mg, 64% of 11 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg to 25 mg | 3 |
| 25 mg to 50 mg | 7 |
| 50 mg to 100 mg | 1 |
Benefit Evidence
Vaginal comfort ↑
Atrophy/cell maturation +25
Circulation ↑, BV ↓16.6%
Research sources
Menstrual comfort (4)
- Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause
PubMed ID: 35550707
RCT showed PM vaginal gel restored atrophic vaginal tissue and improved VHI; objective improvement in local tissues.
- Comparison of the effects of Pueraria mirifica gel and of placebo gel on the vaginal microenvironment of postmenopausal women with Genitourinary Syndrome of Menopause (GSM)
PubMed ID: 32972635
12-week RCT showed PM gel reduced abnormal Nugent scores and improved VHI vs placebo, indicating better vaginal health.
- Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women
PubMed ID: 27749740
12-week randomized trial: vaginal PM gel improved VMI and symptoms though less effectively than conjugated estrogen.
- Effect of Pueraria mirifica on vaginal health
PubMed ID: 17415017
Double-blind RCT showed improved vaginal cell maturation and reduced vaginal dryness over 24 weeks.
Hormone balance (3)
- Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study
PubMed ID: 14971532
Open-label study found substantial reductions in the modified Greene climacteric scale over 6 months.
- Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms
PubMed ID: 20872225
Double-blind dose-comparison showed both doses reduced menopausal symptom scores similarly over 6 months (no placebo).
- Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study
PubMed ID: 17957910
Phase III randomized study showed PM alleviated climacteric symptoms similarly to conjugated estrogen over 6 months.
Blood circulation (1)
- Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause
PubMed ID: 35550707
RCT showed marked decreases in vaginal artery PI/RI (increased vaginal blood flow) vs placebo.
Mood balance (1)
- Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study
PubMed ID: 17957910
Phase III RCT showed large reductions in climacteric symptom scores which include psychological/mood items.
Wellbeing (1)
- Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study
PubMed ID: 17957910
Phase III RCT demonstrating large reduction in climacteric symptoms, reflecting improved overall well‑being.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Pueraria Mirifica
Search all4 products whose verified label declares Pueraria Mirifica — not every bottle that mentions it in a title.